# Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

> **NCT00671970** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 57 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Bevacizumab and Erlotinib

## Key facts

- **NCT ID:** NCT00671970
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-11
- **Final completion:** 2010-04
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2013-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00671970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00671970, "Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00671970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*